Mesoblast’s (MESO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Mesoblast (NASDAQ:MESOFree Report) in a report published on Tuesday, Benzinga reports.

Separately, downgraded Mesoblast from a hold rating to a sell rating in a research note on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. Based on data from, Mesoblast presently has a consensus rating of Hold and a consensus price target of $13.67.

Read Our Latest Report on MESO

Mesoblast Stock Performance

MESO stock opened at $7.14 on Tuesday. The stock’s 50 day simple moving average is $6.80 and its 200 day simple moving average is $3.79. Mesoblast has a fifty-two week low of $1.61 and a fifty-two week high of $10.24. The company has a market cap of $815.25 million, a P/E ratio of -6.37 and a beta of 3.46.

Institutional Trading of Mesoblast

An institutional investor recently bought a new position in Mesoblast stock. Chase Investment Counsel Corp acquired a new position in Mesoblast Limited (NASDAQ:MESOFree Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 59,600 shares of the company’s stock, valued at approximately $298,000. Chase Investment Counsel Corp owned about 0.05% of Mesoblast as of its most recent SEC filing. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Recommended Stories

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with's FREE daily email newsletter.